Product Defect Leads to Recall of Hormone Replacement Therapy

Evamist is approved to teat vasomotor symptoms of menopause
Evamist is approved to teat vasomotor symptoms of menopause

A voluntary recall of 1 batch of Evamist (estradiol transdermal spray) has been initiated by Perrigo due to potential product damage. The recall is being issued at the pharmacy level.

The Company states that cracks in the vial neck near the crimp may result in product evaporation or leaking which would make it difficult for patients to properly dispense the dose. The product has a packaging lot number of MEEF and an expiration date of 4/20; it was distributed between August 17, 2017 and January 3, 2018.

Related Articles

Evamist is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. It is supplied as a homogenous solution of estradiol, octisalate, and alcohol. The liquid formulation is packaged in a glass vial fitted with a metered-dose pump. Each metered-dose pump contains 8.1mL and is designed to deliver 56 sprays of 90mcL after priming; 1 spray contains 1.53mg estradiol. 

Related Links

For more information call 1-855-215-5816 or visit Perrigo.com.